TY - JOUR
T1 - The effect of Plasmodium falciparum malaria on HIV-1 RNA blood plasma concentration
AU - Hoffman, Irving F.
AU - Jere, Charles S.
AU - Taylor, Terrie E.
AU - Munthali, Peter
AU - Dyer, John R.
AU - Wirima, Jack J.
AU - Rogerson, Stephen J.
AU - Kumwenda, Newton
AU - Eron, Joe J.
AU - Fiscus, Susan A.
AU - Chakraborty, Hrishitesh
AU - Taha, Taha E.
AU - Cohen, Myron S.
AU - Molyneux, Malcolm E.
PY - 1999
Y1 - 1999
N2 - Objectives: This study was undertaken to determine the relative effect of malaria infection on HIV concentration in blood plasma, and prospectively to monitor viral concentrations after antimalarial therapy. Design: A prospective, double cohort study was designed to compare the blood HIV-1 RNA concentrations of HIV-positive individuals with and without acute malaria illness. Subjects were followed for 4 weeks after successful malaria therapy, or for 4 weeks from enrollment (controls). Methods: Malawian adults with symptomatic Plasmodium falciparum parasitemia (malaria group) and asymptomatic, aparasitemic blood donors (control group) were tested for HIV-1 antibodies to identify appropriate study groups. The malaria group received antimalarial chemotherapy only and were followed with sequential blood films. In both groups, blood plasma HIV-1 RNA viral concentrations were determined at enrollment and again at 1, 2 and 4 weeks. Results: Forty-seven malaria patients and 42 blood donors were enrolled. At enrollment blood plasma HIV-1 RNA concentrations were approximately sevenfold higher in patients with malaria than in blood donors (medians 15.1 × 104 and 2.24 × 104 copies/ml, respectively, P = 0.0001). No significant changes in median HIV-1 concentrations occurred in the 21 blood donors followed to week 4 (P = 0.68). In the 27 subjects successfully treated for malaria who were followed to week 4, a reduction in plasma HIV-1 RNA was observed from a median of 19.1 × 104 RNA copies/ml at enrollment, to 12.0 × 104 copies/ml at week 4, (P = 0.02). Plasma HIV-1 concentrations remained higher in malaria patients than controls (median 12.0 × 104 compared with 4.17 × 104 copies/ml, P = 0.086). Conclusions: HIV-1 blood viral burden is higher in patients with P. falciparum malaria than in controls and this viral burden can, in some patients, be partly reduced with antimalarial therapy.
AB - Objectives: This study was undertaken to determine the relative effect of malaria infection on HIV concentration in blood plasma, and prospectively to monitor viral concentrations after antimalarial therapy. Design: A prospective, double cohort study was designed to compare the blood HIV-1 RNA concentrations of HIV-positive individuals with and without acute malaria illness. Subjects were followed for 4 weeks after successful malaria therapy, or for 4 weeks from enrollment (controls). Methods: Malawian adults with symptomatic Plasmodium falciparum parasitemia (malaria group) and asymptomatic, aparasitemic blood donors (control group) were tested for HIV-1 antibodies to identify appropriate study groups. The malaria group received antimalarial chemotherapy only and were followed with sequential blood films. In both groups, blood plasma HIV-1 RNA viral concentrations were determined at enrollment and again at 1, 2 and 4 weeks. Results: Forty-seven malaria patients and 42 blood donors were enrolled. At enrollment blood plasma HIV-1 RNA concentrations were approximately sevenfold higher in patients with malaria than in blood donors (medians 15.1 × 104 and 2.24 × 104 copies/ml, respectively, P = 0.0001). No significant changes in median HIV-1 concentrations occurred in the 21 blood donors followed to week 4 (P = 0.68). In the 27 subjects successfully treated for malaria who were followed to week 4, a reduction in plasma HIV-1 RNA was observed from a median of 19.1 × 104 RNA copies/ml at enrollment, to 12.0 × 104 copies/ml at week 4, (P = 0.02). Plasma HIV-1 concentrations remained higher in malaria patients than controls (median 12.0 × 104 compared with 4.17 × 104 copies/ml, P = 0.086). Conclusions: HIV-1 blood viral burden is higher in patients with P. falciparum malaria than in controls and this viral burden can, in some patients, be partly reduced with antimalarial therapy.
UR - http://www.scopus.com/inward/record.url?scp=0033545480&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033545480&partnerID=8YFLogxK
U2 - 10.1097/00002030-199903110-00007
DO - 10.1097/00002030-199903110-00007
M3 - Article
C2 - 10197377
AN - SCOPUS:0033545480
SN - 0269-9370
VL - 13
SP - 487
EP - 494
JO - AIDS
JF - AIDS
IS - 4
ER -